BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9850833)

  • 1. [Clinical studies on the prognostic factors in prostate cancer].
    Horii Y; Yoshida T; Hirai S; Yamauchi T
    Hinyokika Kiyo; 1998 Oct; 44(10):701-5. PubMed ID: 9850833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
    Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.
    Williams SG; Duchesne GM; Millar JL; Pratt GR
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1082-7. PubMed ID: 15519778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
    Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
    Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and statistical studies on prostatic cancer: prognostic value of clinical stage, Gleason score and age].
    Kanamaru H; Shirahase T; Isogawa Y; Moroi S; Okuno H; Kihara Y; Kuo JY; Taniguchi T; Arai Y
    Hinyokika Kiyo; 1994 May; 40(5):387-92. PubMed ID: 8023761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
    J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
    Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.